Insider Buying: Veraxa Biotech (NASDAQ:VRXA) Director Buys $32,700.00 in Stock

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Christoph Samuel Ziegler bought 30,000 shares of Veraxa Biotech stock in a transaction on Tuesday, October 20th. The shares were acquired at an average cost of $1.09 per share, for a total transaction of $32,700.00. Following the completion of the acquisition, the director directly owned 37,932 shares in the company, valued at approximately $41,345.88. The trade was a 378.21% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Veraxa Biotech Trading Down 2.9%

Shares of NASDAQ VRXA opened at $1.00 on Friday. Veraxa Biotech Holding AG has a 52-week low of $0.99 and a 52-week high of $27.36.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research note on Monday, August 31st.

About Veraxa Biotech

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.